Gynecologic Cancers

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Data from the phase 3 LEAP-001 study support lenvatinib plus pembrolizumab as an active combination for endometrial cancer.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.

Data from the phase 3 RUBY trial support the recommendation for dostarlimab plus chemotherapy for patients with advanced MSI-H/dMMR endometrial cancer.

Data from the phase 3 NRG-GY018 trial support the supplemental biologics license application for pembrolizumab plus chemotherapy as a treatment for those with primary advanced or recurrent endometrial cancer.

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.

Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent chemotherapy in stage III to IVA cervical cancer.

Ritu Salani, MD, MBA, discussed the results from the phase 2 SKYSCRAPER-4 trial, which determined tiragolumab plus atezolizumab should not be used to treat PD-L1–positive recurrent cervical cancer.

A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.

The FDA has set a Prescription Drug User Fee Act date of May 9, 2024 for the potential full approval of tisotumab vedotin for those with recurrent or metastatic cervical cancer.

Investigators note a trend towards improved overall survival with cadonilimab plus chemotherapy with or without bevacizumab among those with cervical cancer in the phase 3 AK104-303 trial.

Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.

Results from the phase 3 GCIG INTERLACE trial highlight progression-free survival and overall survival improvements with induction chemotherapy plus chemoradiotherapy for patients with locally advanced cervical cancer.

Progression-free survival benefit appears consistent in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin.

Investigators report acceptable morbidity and health-related quality of life with neoadjuvant chemotherapy plus surgery and concomitant chemoradiotherapy in those with cervical cancer.

The safety profile of tisotumab vedotin-tftv among those with recurrent or metastatic cervical cancer in the phase 3 innovaTV 301 trial appears to be comparable with prior reports of the agent.

In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.

Olvimulogene nanivacirepvec virotherapy plus chemotherapy with or without bevacizumab produces a manageable safety profile in platinum-resistant or platinum-refractory ovarian cancer in the phase 2 VIRO-15 trial.

Avutometinib plus defactinib produces no new safety signals among those with low-grade serous ovarian cancer in the phase 2 RAMP 201 trial.

Maintenance with niraparib also produces benefits in chemotherapy-free interval and time to first and second therapy among those with BRCA wild-type recurrent ovarian cancer in the phase 3 NOVA study.

Health-related quality of life data support dostarlimab plus chemotherapy as a standard of care in primary advanced or recurrent endometrial cancer, according to an expert from Copenhagen University Hospital in Denmark.